[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
September 2005

Pimecrolimus and Tacrolimus for the Treatment of Intertriginous and Facial Psoriasis: Are They Effective?

Author Affiliations

Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005

Arch Dermatol. 2005;141(9):1152-1153. doi:10.1001/archderm.141.9.1152

Commentary 1 on: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.

Gribetz C, Ling M, Lebwohl M, et al

J Am Acad Dermatol. 2004;51:731-738.

Question 1: What is the response of intertriginous psoriasis to topical pimecrolimus in comparison with vehicle?

Design: Randomized, participant- and outcome-evaluator–masked, vehicle-controlled trial.